Exciting Upcoming Presentations for Theriva Biologics
Theriva™ Biologics (NYSE: TOVX) is gearing up for a significant presence at esteemed medical events in the near future. The company has announced presentations at both the European Society for Medical Oncology (ESMO 2025) Annual Congress and the Infectious Diseases Week (IDWeek) 2025 Annual Meeting. These presentations aim to showcase groundbreaking data related to their cancer treatment innovations.
Focus on VCN-01 at ESMO 2025
Insights into the VIRAGE Trial
At ESMO 2025, get ready to learn about the expanded data from the VIRAGE Phase 2b trial involving VCN-01 (zabilugene almadenorepvec). This innovative cancer treatment is set to be featured in a mini-oral presentation, shedding light on its effectiveness against metastatic pancreatic cancer (mPDAC).
Key Presentation Details
- Presenting Author: Dr. Rocío Garcia-Carbonero
- Study Title: VIRAGE trial: randomized Phase IIb, study of Nab-Paclitaxel and Gemcitabine with/without VCN-01
- Date & Time: Monday, October 20, 2025, at 9:28 a.m. CEST
- Session: Mini oral session 2, GI Tumors Upper Digestive
- Location: Bonn Auditorium - Hall 7.1c, Messe Berlin
SYN-004 Shines at IDWeek 2025
Breakthrough Data Presentation
SYN-004 (ribaxamase) is also making waves as it will be presented at IDWeek 2025. The focus will be on the interim blinded safety and pharmacokinetic data from ongoing Phase 1b/2a trials. These studies aim to explore this treatment's effectiveness in allogeneic hematopoietic cell transplant (HCT) recipients.
Presentation Insights
- Presenting Author: Dr. Erik R. Dubberke, MD
- Study Title: Safety and tolerability of SYN-004 in HCT recipients
- Date & Time: Monday, October 20, 2025, from 12:15 to 1:30 p.m. US EDT
- Location: Poster Hall B4-5, Georgia World Congress Center
Understanding VCN-01: A Closer Look
VCN-01 is an intriguing therapy that operates via a unique mechanism. This oncolytic adenovirus selectively targets tumor cells while simultaneously disrupting the tumor's protective stroma, enhancing the efficacy of concurrent chemotherapy and immunotherapy. The potential to treat a range of cancers, including pancreatic ductal adenocarcinoma and head and neck cancers, makes VCN-01 a notable candidate in the field.
What is SYN-004?
SYN-004, designed to maintain intestinal health during antibiotic therapy, is crucial for HCT recipients at risk for Clostridioides difficile infection and other complications. Its recent clinical trial results underscore its potential to preserve gut microbiome integrity, leading to better patient outcomes. The ongoing investigations affirm SYN-004's role in enhancing treatment benefits in vulnerable patient populations.
About Theriva™ Biologics, Inc.
Theriva™ Biologics, based in the clinical-stage arena, is focused on developing important therapeutics targeting unmet medical needs in oncology. Their innovative oncolytic platform includes therapies like VCN-01 and SYN-004, which aim to improve patient outcomes by addressing significant barriers to effective cancer treatment.
Contact Information for Inquiries
If you have any questions or need further details, please reach out to:
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
Email: kgardner@lifesciadvisors.com
Frequently Asked Questions
What presentations is Theriva Biologics attending?
Theriva Biologics is scheduled to present at the ESMO 2025 Congress and IDWeek 2025 Annual Meeting.
What is VCN-01?
VCN-01 is an oncolytic adenovirus designed to selectively target and destroy tumor cells while enhancing access to additional therapies.
What data will be shared at IDWeek 2025?
Data regarding the safety and pharmacokinetics of SYN-004 will be presented, focusing on its efficacy in HCT patients.
How does SYN-004 work?
SYN-004 helps preserve the gut microbiome during antibiotic treatment in HCT recipients, potentially reducing serious complications.
Who can be contacted for more details about the company?
Inquiries can be directed to Kevin Gardner of LifeSci Advisors for more information or clarification.
